But on a lighter note, a good company can see its share price rise well over 100%. For instance, the price of AbbVie Inc.

U.S. drugmaker AbbVie said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental ...

AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...

AbbVie Inc. raised its full-year profit forecast as demand for its top-selling anti-inflammatory drugs, Rinvoq and Skyrizi, ...

With a market cap of $356.2 billion, North Chicago, Illinois-based AbbVie Inc. (ABBV) operates in the pharmaceutical sector.

The purchase is the latest in a slew of efforts to invest in its neuroscience portfolio as Humira faces generic competition.

AbbVie’s Humira missed Wall Street’s expectations in the third quarter but Skyrizi and Rinvoq’s continuing outperformance ...

The acquisition of Aliada Therapeutics gives AbbVie access to a Phase I anti-amyloid antibody as well as the biotech’s novel ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its ...

The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after ...

With a new way to break the blood-brain barrier, an Aliada Therapeutics deal could give the North Chicago drugmaker's ...

AbbVie has entered a definitive agreement to acquire all outstanding equity of Aliada Therapeutics in a deal valued at $1.4bn ...